Sclerotherapy
Conditions
Keywords
sclerotherapy, hypertonic glucose, sodium tetradecyl sulfate
Brief summary
Using of low concentrate sodium tetradecyl sulfate for sclerotherapy of telangiectasias should be no less effective than hypertonic glucose, and have a comparable frequency of adverse events.
Detailed description
For sclerotherapy of telangiectasias are used detergents. These are aggressive substances, which have a high frequency of adverse events. According to histological studies the safest concentration for the treatment of telangiectasias is less than that specified in the official instructions. The concentration of sodium tetradecyl sulfate 0.15% was effective and did not cause any adverse reactions in the treatment of telangiectasias from 0.8 to 1 mm in diameter. Small telangiectases (0.5 mm or less) require the treatment with the less aggressive sclerosing agent. Perhaps, the sodium tetradecyl sulfate 0.15%, 0.1% or even 0.05% and hypertonic glucose may be more effective and safe in this situation.
Interventions
PROCEDURESclerotherapy
Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group
Sponsors
Derzhavin Tambov State University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* women over 18 * single primary or secondary telangiectasias unrelated to the reticular veins * signed informed consent to participate in the study
Exclusion criteria
* telangiectasias associated with reticular veins * diabetes mellitus * pregnancy or lactation * malignant neoplasms * inability or unwillingness of the patient to wear compression stockings * hypersensitivity to one of the drugs * concomitant diseases: bronchial asthma, severe liver and kidney disease, acute thrombosis and thrombophlebitis, infection of the skin and/or soft tissues, infectious diseases, arteriosclerosis, diabetic angiopathy, heart defects requiring surgery, fever, toxic hyperthyroidism, obesity, tuberculosis, sepsis, violation of the cellular composition of the blood, all diseases requiring bed rest, heart disease with decompensation phenomena, known hereditary thrombophilia. * period after treatment of alcoholism * reception of oral contraceptives * sedentary lifestyle
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disappearance of the telangiectasia | 2 months | The clearing of the vessels on the six-point scale (from 0 to 5 points): 5 - total disappearance of the matting (100% efficacy), 4 - disappearance of around 80%, 3 - disappearance of around 60%, 2 - disappearance of around 40%, 1 - disappearance of around 20%, 0 - no changes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain during the procedure: visual analog scale | immediately after the procedure | Estimate of the pain on visual analog scale. Visual analog scale \[VAS\] is a measure of pain intensity. It is a continuous scale comprised of a horizontal 10 cm length: no pain (score of 0) and pain as bad as it could be or worst imaginable pain (score of 10). |
| Patient Satisfaction After Treatment | 2 months | Assessment of patient satisfaction on the 3-point scale : * no result (0 points), * incomplete satisfaction (1 point), * complete satisfaction (2 points) |
Countries
Russia
Outcome results
None listed